Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 31248604.
- Also identified by DOI 10.1016/j.eururo.2019.06.014 and PMC identifier 6922301.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Retrospective studies in selected patients have demonstrated a survival benefit with prostatectomy or radiotherapy (RT) of the primary tumor in metastatic hormone-sensitive prostate cancer (mHSPC). However, there is currently not enough evidence to recommend RT to the primary tumor as the standard of care for patients treated with androgen deprivation therapy plus abiraterone or docetaxel for low-volume mHSPC.
Medical subject headings
- Androgen Antagonists
- Androstenes
- Docetaxel
- Neoplasm Metastasis
- Prostatectomy
- Prostatic Neoplasms
- Radiotherapy